The patients with intermediate-high risk pulmonary embolism who have acute right
ventricular (RV) dysfunction and myocardial injury without overt hemodynamic compromise …

Background Optimal dosing of the recombinant tissue-type plasminogen activator (rt-PA) is
important in treating pulmonary thromboembolism (PTE). The aim of this study was to …

Study objective To test the hypothesis that a reduced dose of bolus recombinant human
tissue-type plasminogen activator (rt-PA)(0.6 mg/kg/15 min, maximum of 50 mg) would result …

We analyzed a large series that included 289 patients with proven extensive PE complicated
with severe pulmonary arterial hypertension and right ventricular dysfunction; high dose and …

Recombinant human tissue-type plasminogen activator (rt-PA), a relatively clot-specific
fibrinolytic agent, represents a novel and promising approach to thrombolytic therapy of …

Acute pulmonary embolism (PE) is a life-threating condition with high morbidity and
mortality. While current guidelines recommend systemic thrombolysis for patients with high …

Objectives: To investigate the efficacy and safety of initial thrombolysis by recombinant
tissue-type plasminogen activator (rt-PA) in compared with anticoagulant therapy in patients …

Animal studies have demonstrated that thrombolysis with recombinant tissue-type
plasminogen activator (rt-PA) is accelerated and that bleeding is reduced when rt-PA is …

PURPOSE: The risk factors for bleeding in patients receiving recombinant tissue-type
plasminogen activator for massive pulmonary embolism are not known. PATIENTS AND …

Acute pulmonary embolism is an important emergency disease which frequently results in
life-threatening complication. Systemic fibrinolysis is recommended as standard, first-line …